Farnesyltransferase inhibitors: Novel compounds in development for the treatment of myeloid malignancies
Author:
Publisher
Elsevier BV
Subject
Hematology
Reference33 articles.
1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia;Druker;N Engl J Med,2001
2. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse;Sievers;J Clin Oncol,2001
3. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho;Lebowitz;Oncogene,1998
4. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology;Prendergast;Histol Histopathol,2001
5. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development;Rowinsky;J Clin Oncol,1999
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases;Expert Opinion on Investigational Drugs;2019-02-27
2. 5q– myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics;Oncogene;2009-07-13
3. Ras as a therapeutic target in hematologic malignancies;Expert Opinion on Emerging Drugs;2007-05
4. Clinical activity of tipifarnib in hematologic malignancies;Expert Opinion on Investigational Drugs;2007-02-16
5. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines;Leukemia;2007-02-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3